Preclinical data of Emergent BioSolutions' ES414 in mCRPC presented at PEGS 2013

Emergent BioSolutions Inc. (NYSE: EBS) today announced that it presented preclinical data on its lead bispecific ADAPTIR^TM (Modular Protein Technology) molecule, ES414, at the 9^th Annual Protein and Antibody Engineering Summit (PEGS), currently underway in Boston, MA. ES414 is being developed as a potential therapeutic for metastatic castration-resistant prostate cancer (mCRPC). Emergent recently presented pharmacokinetic and tolerability results at the American Association for Cancer Research annual meeting in Washington, D.C.

“Tolerability Assessment of ES414, an Anti-PSMA x Anti-CD3 ADAPTIR Molecule”

The ES414 molecule selectively binds to the T cell receptor on cytotoxic T cells and Prostate Specific Membrane Antigen (PSMA), an antigen commonly found on prostate cancer cells. In preclinical studies, ES414 has been shown to redirect T-cell cytotoxicity (RTCC) towards prostate cancer cells expressing PSMA.

The poster, "Tolerability Assessment of ES414, an Anti-PSMA x Anti-CD3 ADAPTIR Molecule," presented results of preclinical studies demonstrating that ES414 is pharmacologically active, well tolerated in toxicology models at levels well above the expected human dose, possesses suitable characteristics for additional in vivo toxicology studies, and merits further investigation as a potential therapeutic for mCRPC treatment.

"The ES414 product candidate is a unique molecule developed from our ADAPTIR technology platform. The preclinical data are encouraging and the molecule has a number of advantages; specifically, activity at very low doses, minimal cytokine release on binding to target and T cells, and a long half-life. Additionally, we have a defined, scalable manufacturing process in place for ES414 to supply future clinical demands. The manufacturing process is fairly standard and is similar to that for making monoclonal antibodies. We look forward to filing an Investigational New Drug application next year," said W. James Jackson, Ph.D., Chief Scientific Officer at Emergent BioSolutions.